Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Hypertension Reports
Erschienen in: Current Hypertension Reports 7/2016

01.07.2016 | Preeclampsia (VD Garovic, Section Editor)

Aspirin vs Heparin for the Prevention of Preeclampsia

verfasst von: Vasiliki Katsi, Theoni Kanellopoulou, Thomas Makris, Petros Nihoyannopoulos, Efrosyni Nomikou, Dimitrios Tousoulis

Erschienen in: Current Hypertension Reports | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

Preeclampsia is a hypertensive disorder of pregnancy that remains a significant cause of maternal morbidity and mortality worldwide. Preeclampsia can be resolved by delivery, and most of the proposed preventive treatment approaches are based on processes involved in placental development in early pregnancy. Yet, none of these has been established in clinical practice. Low-dose aspirin is the most promising candidate, nevertheless; while some individual randomized controlled trials showed minimal or no statistically significant benefit, recent metanalyses showed that early initiation before 16 weeks of gestation is associated with prevention of early-onset preeclampsia and reduction in prevalence of perinatal death or morbidity of pregnant women. Heparin could be an alternative antithrombotic and anti-inflammatory median to prevent preeclampsia either alone or in combination with aspirin; however, results are conflicting concerning efficacy.
Literatur
1.
2.
Angeli F, Angeli E, Reboldi G, Verdecchia P. Hypertensive disorders during pregnancy: clinical applicability of risk prediction models. J Hypertens. 2011;29:2320–3.CrossRefPubMed
3.
Milne F, Redman C, Walker J, Baker P, Bradley J, Cooper C, et al. The pre-eclampsia community guideline (PRECOG): how to screen for and detect onset of pre-eclampsia in the community. BMJ. 2005;330:576–80.CrossRefPubMedPubMedCentral
4.
Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141, e691S-736S.PubMed
5.
Schiff E, Peleg E, Goldenberg M, Rosenthal T, Ruppin E, Tamarkin M, et al. The use of aspirin to prevent pregnancy-induced hypertension and lower the ratio of thromboxane A2 to prostacyclin in relatively high risk pregnancies. N Engl J Med. 1989;321:351–6.CrossRefPubMed
6.
Wallenburg HC, Dekker GA, Makovitz JW, Rotmans P. Low-dose aspirin prevents pregnancy-induced hypertension and pre-eclampsia in angiotensin-sensitive primigravidae. Lancet. 1986;1:1–3.CrossRefPubMed
7.
Beaufils M, Uzan S, Donsimoni R, Colau JC. Prevention of pre-eclampsia by early antiplatelet therapy. Lancet. 1985;1:840–2.CrossRefPubMed
8.
McParland P, Pearce JM, Chamberlain GV. Doppler ultrasound and aspirin in recognition and prevention of pregnancy-induced hypertension. Lancet. 1990;335:1552–5.CrossRefPubMed
9.
Sibai BM, Caritis SN, Thom E, Klebanoff M, McNellis D, Rocco L, et al. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The National Institute of Child Health and Human Development Network of Maternal Fetal Medicine Units. N Engl J Med. 1993;329:1213–8.CrossRefPubMed
10.
Bower SJ, Harrington KF, Schuchter K, McGirr C, Campbell S. Prediction of pre-eclampsia by abnormal uterine Doppler ultrasound and modification by aspirin. Br J Obstet Gynaecol. 1996;103:625–9.CrossRefPubMed
11.
Harrington K, Kurdi W, Aquilina J, England P, Campbell S. A prospective management study of slow-release aspirin in the palliation of uteroplacental insufficiency predicted by uterine artery Doppler at 20 weeks. Ultrasound Obstet Gynecol. 2000;15:13–8.CrossRefPubMed
12.
Vainio M, Kujansuu E, Iso-Mustajärvi M, Mäenpää J. Low dose acetylsalicylic acid in prevention of pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches. BJOG. 2002;109:161–7.CrossRefPubMed
13.
Ebrashy A, Ibrahim M, Marzook A, Yousef D. Usefulness of aspirin therapy in high-risk pregnant women with abnormal uterine artery Doppler ultrasound at 14–16 weeks pregnancy: randomized controlled clinical trial. Croat Med J. 2005;46:826–31.PubMed
14.
CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet. 1994;343: 619–29
15.
Low-dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy-induced hypertension. Italian study of aspirin in pregnancy. Lancet. 1993; 341:396–400
16.
ECPPA. randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women. ECPPA (Estudo Colaborativo para Prevenção da Pré-eclampsia com Aspirina) Collaborative Group. Br J Obstet Gynaecol. 1996;103:39–47.CrossRef
17.
Caritis S, Sibai B, Hauth J, Lindheimer MD, Klebanoff M, Thom E, et al. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med. 1998;338:701–5.CrossRefPubMed
18.
Subtil D, Goeusse P, Puech F, Lequien P, Biausque S, Breart G, et al. Aspirin (100 mg) used for prevention of pre-eclampsia in nulliparous women: the Essai Régional Aspirine Mère Enfant study (Part 1). BJOG. 2003;110:475–84.PubMed
19.
Walsh SW, Wang Y. Maternal perfusion with low-dose aspirin preferentially inhibits placental thromboxane while sparing prostacyclin. Hypertens Pregnancy. 1998;17:203–15.CrossRef
20.
Hauth J, Sibai B, Caritis S, VanDorsten P, Lindheimer M, Klebanoff M, et al. Maternal serum thromboxane B2 concentrations do not predict improved outcomes in high-risk pregnancies in a low-dose aspirin trial. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medical Units. Am J Obstet Gynecol. 1998;179:1193–9.CrossRefPubMed
21.•
Park F, Russo K, Williams P, Pelosi M, Puddephatt R, Walter M, et al. Prediction and prevention of early-onset pre-eclampsia: impact of aspirin after first-trimester screening. Ultrasound Obstet Gynecol. 2015;46:419–23. This article is a retrospective analysis of two consecutive cohorts screened for early PE, and results have shown that administration of aspirin before 16 weeks of gestation significantly reduces the prevalence of early preeclampsia by 90%.CrossRefPubMed
22.
Odibo AO, Goetzinger KR, Odibo L, Tuuli MG. Early prediction and aspirin for prevention of pre-eclampsia (EPAPP) study: a randomized controlled trial. Ultrasound Obstet Gynecol. 2015;46:414–8.CrossRefPubMed
23.
Moore GS, Allshouse AA, Post AL, Galan HL, Heyborne KD. Early initiation of low-dose aspirin for reduction in preeclampsia risk in high-risk women: a secondary analysis of the MFMU High-Risk Aspirin Study. J Perinatol. 2015;35(5):328–31.CrossRefPubMed
24.
Villa PM, Kajantie E, Räikkönen K, Pesonen AK, Hämäläinen E, Vainio M, et al. Aspirin in the prevention of pre-eclampsia in high-risk women: a randomised placebo-controlled PREDO Trial and a meta-analysis of randomised trials. BJOG. 2013;120:64–74.CrossRefPubMed
25.
Chiaffarino F, Parazzini F, Paladini D, Acaia B, Ossola W, Marozio L, et al. A small randomized trial of low-dose aspirin in women at high risk of pre-eclampsia. Eur J Obstet Gynecol Reprod Biol. 2004;112:142–4.CrossRefPubMed
26.
Bakhti A, Vaiman D. Prevention of gravidic endothelial hypertension by aspirin treatment administered from the 8th week of gestation. Hypertens Res. 2011;34:1116–20.CrossRefPubMed
27.
Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol. 2010;116:402–14.CrossRefPubMed
28.
Xu TT, Zhou F, Deng CY, Huang GQ, Li JK, Wang XD. Low-dose aspirin for preventing preeclampsia and its complications: a meta-analysis. J Clin Hypertens (Greenwich). 2015;17:567–73.CrossRef
29.
Askie LM, Duley L, Henderson-Smart DJ, Stewart LA, PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet. 2007;369:1791–8.CrossRefPubMed
30.
Roberge S, Villa P, Nicolaides K, Giguère Y, Vainio M, Bakthi A, et al. Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagn Ther. 2012;31:141–6.CrossRefPubMed
31.
Roberge S, Giguère Y, Villa P, Nicolaides K, Vainio M, Forest JC, et al. Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. Am J Perinatol. 2012;29:551–6.PubMed
32.
Hermida RC, Ayala DE, Fernández JR, Mojón A, Alonso I, Silva I, et al. Administration time-dependent effects of aspirin in women at differing risk for preeclampsia. Hypertension. 1999;34:1016–23.CrossRefPubMed
33.
Hermida RC, Ayala DE, Iglesias M, Mojón A, Silva I, Ucieda R, et al. Time-dependent effects of low-dose aspirin administration on blood pressure in pregnant women. Hypertension. 1997;30:589–95.CrossRefPubMed
34.
Rodger MA, Carrier M, Le Gal G, Martinelli I, Perna A, Rey E, et al. Meta-analysis of low molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications. Blood. 2014;123:822–8.CrossRefPubMed
35.
Christopherson 2nd KW, Campbell JJ, Travers JB, Hromas RA. Low-molecular-weight heparins inhibit CCL21-induced T cell adhesion and migration. J Pharmacol Exp Ther. 2002;302:290–5.CrossRefPubMed
36.
Hills FA, Abrahams VM, González-Timón B, Francis J, Cloke B, Hinkson L, et al. Heparin prevents programmed cell death in human trophoblast. Mol Hum Reprod. 2006;12:237–43.CrossRefPubMed
37.
Oberkersch R, Attorresi AI, Calabrese GC. Low molecular-weight heparin inhibition in classical complement activation pathway during pregnancy. Thromb Res. 2010;125:e240–5.CrossRefPubMed
38.
Quenby S, Mountfield S, Cartwright JE, Whitley GS, Vince G. Effects of low-molecular-weight and unfractionated heparin on trophoblast function. Obstet Gynecol. 2004;104:354–61.CrossRefPubMed
39.
Ganapathy R, Whitley GS, Cartwright JE, Dash PR, Thilaganathan B. Effect of heparin and fractionated heparin on trophoblast invasion. Hum Reprod. 2007;22:2523–7.CrossRefPubMed
40.
Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 2004;10:1222–6.CrossRefPubMed
41.
Hirsh J, Anand SS, Halperin JL, Fuster V, American Heart Association. Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association. Circulation. 2001;103:2994–3018.CrossRefPubMed
42.
Chamley LW. Antiphospholipid antibodies: biological basis and prospects for treatment. J Reprod Immunol. 2002;57:185–202.CrossRefPubMed
43.
Franklin RD, Kutteh WH. Effects of unfractionated and low molecular weight heparin on antiphospholipid antibody binding in vitro. Obstet Gynecol. 2003;101:455–62.PubMed
44.
Tzafettas J, Mamopoulos A, Anapliotis A, Loufopoulos A, Psarra A, Klearchou N, et al. Thromboprophylaxis throughout pregnancy in women with previous history of recurrent miscarriages of unknown aetiology. ClinExpObstet Gynecol. 2002;29:267–70.
45.
Schleussner E, Kamin G, Seliger G, Rogenhofer N, Ebner S, Toth B, et al. Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: a multicenter trial with a minimization randomization scheme. Ann Intern Med. 2015;162(9):601–9.CrossRefPubMed
46.
Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol. 2002;100:408–13. Erratum in: ObstetGynecol 2002;100:1361.PubMed
47.
Rey E, Garneau P, David M, Gauthier R, Leduc L, Michon N, et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost. 2009;7(1):58–64.CrossRefPubMed
48.
Gris JC, Chauleur C, Faillie JL, Baer G, Marès P, Fabbro-Peray P, et al. Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae. The pilot randomised controlled NOH-AP trial. Thromb Haemost. 2010;104(4):771–9.CrossRefPubMed
49.•
Martinelli I, Ruggenenti P, Cetin I, Pardi G, Perna A, Vergani P, et al. Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood. 2012;119(14):3269–75. The findings of this trial showed no statistical difference in prevention of recurrent late pregnancy complications with prophylactic dose of low-molecular weight heparin.CrossRefPubMedPubMedCentral
50.
Rodger MA, Hague WM, Kingdom J, Kahn SR, Karovitch A, Sermer M, et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet. 2014;384(9955):1673–83.CrossRefPubMed
51.
Goel N, Tuli A, Choudhry R. The role of aspirin versus aspirin and heparin in cases of recurrent abortions with raised anticardiolipin antibodies. Med Sci Monit. 2006;12(3):CR132–6.PubMed
52.
Visser J, Ulander VM, Helmerhorst FM, Lampinen K, Morin-Papunen L, Bloemenkamp KW, et al. Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. HABENOX: a randomized multicentre trial. Thromb Haemost. 2011;105(2):295–301.CrossRefPubMed
53.
de Vries JI, van Pampus MG, Hague WM, Bezemer PD, Joosten JH, FRUIT Investigators. Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. J Thromb Haemost. 2012;10(1):64–72.CrossRefPubMed
54.
van Hoorn ME, Hague WM, van Pampus MG, Bezemer D, de Vries JI, FRUIT investigators. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. Eur J Obstet Gynecol Reprod Biol. 2015;197:168–73.CrossRefPubMed
55.
Abheiden C, Van Hoorn ME, Hague WM, Kostense PJ, van Pampus MG, de Vries J. Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial Doppler in women with a history of early onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. BJOG. 2015
56.••
Roberge S, Demers S, Nicolaides KH, Bureau M, Côté S, Bujold E. Prevention of pre-eclampsia by low-molecular weight heparin in addition to aspirin: a meta-analysis. Ultrasound Obstet Gynecol. 2015. A recent review and metanalysis that showed that the addition of LMWH to low-dose aspirin could reduce the prevalence of preeclampsia in women with history of preeclampia.
57.
Viinikka L, Hartikainen-Sorri AL, Lumme R, Hiilesmaa V, Ylikorkala O. Low dose aspirin in hypertensive pregnant women: effect on pregnancy outcome and prostacyclin-thromboxane balance in mother and newborn. Br J Obstet Gynaecol. 1993;100:809–15.CrossRefPubMed
58.
Morris JM, Fay RA, Ellwood DA, Cook CM, Devonald KJ. A randomized controlled trial of aspirin in patients with abnormal uterine artery blood flow. Obstet Gynecol. 1996;87:74–8.CrossRefPubMed
59.
Byaruhanga RN, Chipato T, Rusakaniko S. A randomized controlled trial of low-dose aspirin in women at risk from pre-eclampsia. Int J Gynaecol Obstet. 1998;60:129–35.CrossRefPubMed
60.
Yu CK, Papageorghiou AT, Parra M, Palma Dias R, Nicolaides KH, Fetal Medicine Foundation Second Trimester Screening Group. Randomized controlled trial using low-dose aspirin in the prevention of pre-eclampsia in women with abnormal uterine artery Doppler at 23 weeks’ gestation. Ultrasound Obstet Gynecol. 2003;22(3):233–9.CrossRefPubMed
Metadaten
Titel
Aspirin vs Heparin for the Prevention of Preeclampsia
verfasst von
Vasiliki Katsi
Theoni Kanellopoulou
Thomas Makris
Petros Nihoyannopoulos
Efrosyni Nomikou
Dimitrios Tousoulis
Publikationsdatum
01.07.2016
Verlag
Springer US
Erschienen in
Current Hypertension Reports / Ausgabe 7/2016
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-016-0664-3

Weitere Artikel der Ausgabe 7/2016

Current Hypertension Reports 7/2016 Zur Ausgabe

Secondary Hypertension: Nervous System Mechanisms (M Wyss, Section Editor)

Obesity-Induced Hypertension: Brain Signaling Pathways

Hypertension and Emergency Medicine (T Rainer, Section Editor)

Asking the Patient or Measuring Blood Pressure in the Emergency Department: Which One is Best?

Guidelines/Clinical Trials/Meta-Analysis (J Kostis, Section Editor)

Renal Denervation: a Field in Flux

Prevention of Hypertension: Public Health Challenges (P Muntner, Section Editor)

A Systematic Review of Beliefs About Hypertension and its Treatment Among African Americans

Secondary Hypertension: Nervous System Mechanisms (M Wyss, Section Editor)

Obstructive Sleep Apnoea and Hypertension: the Role of the Central Nervous System

Therapeutic Trials (M Weir, Section Editor)

New Agents in Treatment of Hyperkalemia: an Opportunity to Optimize Use of RAAS Inhibitors for Blood Pressure Control and Organ Protection in Patients with Chronic Kidney Disease

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Metformin rückt in den Hintergrund

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise